Skip to main navigation Skip to search Skip to main content

The effects of commercially available preservative-free FDA-approved triamcinolone (Triesence®) on retinal cells in culture

  • Leandro Cabral Zacharias
  • , Maria Fernanda Estrago-Franco
  • , Claudio Ramirez
  • , Maria Cristina Kenney
  • , Walter Y. Takahashi
  • , Gail M. Seigel
  • , Baruch D. Kuppermann

Research output: Contribution to journalArticlepeer-review

8 Scopus citations

Abstract

Purpose: To evaluate the effects of Triesence® (TRI), a new preservative-free triamcinolone approved by the U.S. Food and Drug Administration (FDA) for intraocular use, on human retina pigment epithelial (ARPE-19) and rat neurosensory (R28) cells in culture. Methods: ARPE-19 and R28 cell cultures were treated 24h with 1,000, 500, 200, or 100μg/mL of crystalline (cTRI) or 1,000, 500, or 200μg/mL of solubilized (sTRI). TRI was solubilized by centrifuging the drug, discarding the supernatant containing the vehicle and then resuspending the drug pellet in an equivalent amount of Dimethyl sulfoxide to achieve the same concentration as the commercial preparation. Percentage of cell viability (CV) was evaluated by a trypan blue dye-exclusion assay. The mitochondrial membrane potential (ΔΨm) was analyzed with the JC-1 assay. The caspase-3/7 activity was measured by a fluorochrome assay. Results: In the ARPE-19 cultures, the cTRI caused a decrease in CV at 1,000μg/mL (13.03±6.51; P<0.001), 500μg/mL (28.87±9.3; P<0.001), 200μg/mL (54.93±5.61; P<0.001), and 100μg/mL (82.53±0.65; P<0.005) compared with the untreated controls (96.98±0.16). In R28 cultures, the cTRI treatment also reduced CV values significantly (P<0.001) for the 1,000μg/mL (22.73±2.44), 500μg/mL (34.63±1.91), 200μg/mL (58.70±1.39), and 100μg/m (75.33±2.47) compared with the untreated controls (86.08±3.54). Once the TRI was solubilized (sTRI), the CV and ΔΨm remained similar to the untreated controls for both ARPE-19 and R28 cells. The sTRI treatment with 1,000, 500, and 200μg/mL increased in caspase-3/7 activity in ARPE-19 cells (P<0.01) and in R28 cells (P<0.05) compared with dimethyl sulfoxide equivalent controls. Conclusion: The crystalline form of TRI (cTRI) can cause a significant decrease in CV to cultured retinal cells. Once the TRI is solubilized (sTRI), at the same concentrations, the cells remain viable with no decrease in CV or ΔΨm. The sTRI can, however, increase caspase-3/7 activity, thus suggesting some degree of apoptosis.

Original languageEnglish
Pages (from-to)143-150
Number of pages8
JournalJournal of Ocular Pharmacology and Therapeutics
Volume27
Issue number2
DOIs
StatePublished - Apr 1 2011

Fingerprint

Dive into the research topics of 'The effects of commercially available preservative-free FDA-approved triamcinolone (Triesence®) on retinal cells in culture'. Together they form a unique fingerprint.

Cite this